<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="choroid" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">choroid</book-part-id>
      <title-group>
        <title>Choroideremia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>MacDonald</surname>
            <given-names>Ian M</given-names>
          </name>
          <degrees>MD, CM</degrees>
          <aff>Professor, Department of Ophthalmology and Visual Sciences<break/>University of Alberta<break/>Edmonton, Alberta, Canada</aff>
          <email>macdonal@ualberta.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hume</surname>
            <given-names>Stacey</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Joint Laboratory Head and Associate Professor, Molecular Diagnostics Laboratory<break/>Department of Medical Genetics<break/>University of Alberta<break/>Edmonton, Alberta, Canada</aff>
          <email>shume@ualberta.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chan</surname>
            <given-names>Stephanie</given-names>
          </name>
          <degrees>MSc</degrees>
          <aff>Genetic Counsellor, Department of Ophthalmology and Visual Sciences<break/>University of Alberta<break/>Royal Alexandra Hospital<break/>Edmonton, Alberta, Canada</aff>
          <email>stephanie.chan@albertahealthservices.ca</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Seabra</surname>
            <given-names>Miguel C</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Biomedical Sciences<break/>Imperial College School of Medicine<break/>London, United Kingdom</aff>
          <email>m.seabra@imperial.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>2</month>
          <year>2003</year>
        </date>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>28</day>
          <month>5</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="chac" document-type="chapter">Chorea-Acanthocytosis</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cgd" document-type="chapter">Chronic Granulomatous Disease</related-object>
      <abstract id="choroid.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Choroideremia (CHM) is characterized by progressive chorioretinal degeneration in affected males and milder signs in carrier females. Typically, symptoms in affected males evolve from night blindness to peripheral visual field loss, with central vision preserved until late in life. Although carrier females are generally asymptomatic, signs of chorioretinal degeneration can be observed with careful fundus examination. These signs become more readily apparent after the second decade.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of CHM can be made clinically, based on the fundus examination and family history consistent with X-linked inheritance. The diagnosis is confirmed with the identification of a pathogenic variant in <italic toggle="yes">CHM</italic> which encodes the protein REP-1.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Surgical correction of retinal detachment and cataract as needed; UV-blocking sunglasses for outdoors; appropriate dietary intake of fresh fruit, leafy green vegetables; antioxidant vitamin supplement as needed; regular intake of dietary omega-3 very-long-chain fatty acids, including docosahexaenoic acid; low vision services as needed; counseling as needed to help cope with depression, loss of independence, fitness for driving, and anxiety over job loss.</p>
          <p><italic toggle="yes">Surveillance:</italic> Periodic ophthalmologic examination and Goldmann visual field examinations to monitor progression.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> UV exposure from sunlight reflected from water and snow.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CHM is inherited in an X-linked manner. An affected male transmits the pathogenic variant to all of his female offspring and none of his male offspring. A carrier female has a 50% chance of passing the pathogenic variant to her offspring: males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and will usually not be affected. Carrier testing for at-risk female relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="choroid.Diagnosis">
        <title>Diagnosis</title>
        <sec id="choroid.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Diagnosis of choroideremia (CHM) should be suspected in individuals with the following findings:</p>
          <p><bold>Affected males.</bold> The diagnosis of choroideremia (CHM) can be made if the following are present [<xref ref-type="bibr" rid="choroid.REF.roberts.2002.658">Roberts et al 2002</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>A history of defective dark adaptation.</bold> Poor vision in the dark is commonly the first symptom in affected males. Males may not note such symptoms until their early teens.</p>
            </list-item>
            <list-item>
              <p><bold>Characteristic fundus appearance.</bold> Patchy areas of chorioretinal degeneration generally begin in the mid-periphery of the fundus. The areas of chorioretinal degeneration progress to marked loss of the retinal pigment epithelium and choriocapillaris (inner of the two vascular layers of the choroid that is composed largely of capillaries) with preservation of the deep choroidal vessels, as demonstrated by intravenous fluorescein angiography. The function and anatomy of the central macula is preserved until late in the disease process.</p>
            </list-item>
            <list-item>
              <p><bold>Peripheral visual field loss.</bold> Peripheral visual field loss manifests as a ring scotoma and generally follows changes in the fundus appearance. Areas of visual field loss closely match areas of chorioretinal degeneration.</p>
            </list-item>
            <list-item>
              <p><bold>The electroretinogram (ERG)</bold> of affected males may at first show a pattern of rod-cone degeneration, which eventually becomes non-recordable.</p>
            </list-item>
            <list-item>
              <p>
                <bold>Family history consistent with X-linked inheritance</bold>
              </p>
            </list-item>
          </list>
          <p>
            <bold>Carrier females</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Fundus appearance.</bold> Carrier females have fundus changes that are similar to those in affected males and follow a similar pattern of progression.</p>
            </list-item>
            <list-item>
              <p><bold>No visual complaints.</bold> Carrier females do not experience significant visual impairment and in general are asymptomatic.</p>
            </list-item>
            <list-item>
              <p><bold>Test results.</bold> Carrier females may show changes with ERG, dark adaptation, and visual field testing.</p>
              <list list-type="bullet">
                <list-item>
                  <p>The ERG may be normal in obligate carriers or in carriers with characteristic fundus changes. <xref ref-type="bibr" rid="choroid.REF.sieving.1986.361">Sieving et al [1986]</xref> demonstrated that although abnormal responses may be recorded in female carriers with a dim blue flash, a dark-adapted white flash, or a flickering stimulus, no one test consistently predicted carrier status.</p>
                </list-item>
                <list-item>
                  <p>Fundus autofluorescence may demonstrate in female carriers patchy areas of loss of fluorescence throughout the fundus [<xref ref-type="bibr" rid="choroid.REF.preising.2009">Preising et al 2009</xref>].</p>
                </list-item>
                <list-item>
                  <p>Carrier females age 21-65 years had no change in the Arden ratio of the electrooculogram [<xref ref-type="bibr" rid="choroid.REF.yau.2007.147">Yau et al 2007</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="choroid.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of choroideremia is established in a proband with the identification of a pathogenic variant in <italic toggle="yes">CHM</italic> (see <xref ref-type="table" rid="choroid.T.summary_of_molecular_genetic_t">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, <bold>use of a multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Single-gene testing</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Sequence analysis of <italic toggle="yes">CHM</italic> is performed first, followed by deletion/duplication analysis if no pathogenic variant is found.</p>
                </list-item>
                <list-item>
                  <p>Targeted analysis for pathogenic variants is performed first in individuals of Finnish ancestry.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CHM</italic> and other genes of interest (see <xref ref-type="sec" rid="choroid.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of CHM. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <p><bold>For individuals with atypical findings</bold> (see <xref ref-type="sec" rid="choroid.Genetically_Related_Allelic_Diso">Genetically Related Disorders</xref>), a different testing strategy should be considered.</p>
          <list list-type="bullet">
            <list-item>
              <p>For males presenting with choroideremia in addition to cognitive issues, and/or hearing loss, testing should begin with a chromosomal microarray (CMA) to look for a large contiguous deletion that includes <italic toggle="yes">CHM.</italic></p>
            </list-item>
            <list-item>
              <p>For symptomatic females in whom a <italic toggle="yes">CHM</italic> pathogenic variant is not identified, a karyotype may be considered to look for an X:autosome translocation resulting in a disruption of <italic toggle="yes">CHM</italic>.</p>
            </list-item>
          </list>
          <table-wrap id="choroid.T.summary_of_molecular_genetic_t" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Choroideremia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_2">Test Method</th>
                  <th id="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3" id="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                  <th headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3" id="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Females</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CHM</italic>
                  </td>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_1" rowspan="2" valign="middle" align="left" colspan="1">95%&#x000a0;<sup>3,&#x000a0;4</sup></td>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>3,&#x000a0;5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_2" valign="top" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" colspan="1" align="left" rowspan="1">Unknown</td>
                </tr>
                <tr>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_1 hd_h_choroid.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">Most pathogenic variants in the Finnish population</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="choroid.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="choroid" object-id="choroid.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="choroid.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="choroid.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="choroid.TF.1.3">
                <label>3. </label>
                <p><xref ref-type="bibr" rid="choroid.REF.van_den_hurk.1997.110">van den Hurk et al [1997]</xref>, <xref ref-type="bibr" rid="choroid.REF.fujiki.1999.735">Fujiki et al [1999]</xref>, <xref ref-type="bibr" rid="choroid.REF.mctaggart.2002.189">McTaggart et al [2002]</xref>, <xref ref-type="bibr" rid="choroid.REF.van_den_hurk.2003.268">van den Hurk et al [2003]</xref>, Freund (MSc thesis, University of Alberta, unpublished)</p>
              </fn>
              <fn id="choroid.TF.1.4">
                <label>4. </label>
                <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation may require additional testing by deletion/duplication analysis.</p>
              </fn>
              <fn id="choroid.TF.1.5">
                <label>5. </label>
                <p>Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</p>
              </fn>
              <fn id="choroid.TF.1.6">
                <label>6. </label>
                <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="choroid.TF.1.7">
                <label>7. </label>
                <p>Targeted analysis that detects <xref ref-type="table" rid="choroid.T.chm_pathogenic_variants_discus">c.1609+2dupT</xref> [<xref ref-type="bibr" rid="choroid.REF.sankila.1992.109">Sankila et al 1992</xref>] for individuals of Finnish ancestry. Note: Pathogenic variants included in a panel may vary by laboratory.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v22/n4/full/ejhg2013183a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="choroid.REF.moosajee.2014">Moosajee et al 2014</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="choroid.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="choroid.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Affected males.</bold> Choroideremia (CHM) is characterized by progressive chorioretinal degeneration in affected males. Typically, symptoms evolve from night blindness to peripheral visual field loss, with central vision preserved until late in life. Males in their 40s have very good visual acuity but only a small visual field. Later, around age 50-70 years, the central vision is lost.</p>
          <p>A study of 115 males with CHM confirmed the typically slow rate of visual acuity loss and the generally good prognosis for central visual acuity retention until the seventh decade [<xref ref-type="bibr" rid="choroid.REF.roberts.2002.658">Roberts et al 2002</xref>]. In that study, 84% of males under age 60 years had visual acuity of 20/40 or better and 35% of individuals over age 60 years had a visual acuity of 20/200 or worse.</p>
          <p>Posterior subcapsular cataracts are found in 31% of males.</p>
          <p>Cystoid macular edema (CME) has been identified in patients with choroideremia. <xref ref-type="bibr" rid="choroid.REF.genead.2011.84">Genead &#x00026; Fishman [2011]</xref> reviewed 16 patients without lesions by fundus examination; ten patients (62.5%) showed a degree of CME on spectral-domain optical coherence tomography.</p>
          <p><bold>Carrier females.</bold> Carrier females are generally asymptomatic; however, signs of chorioretinal degeneration can be observed with careful fundus examination. These signs become more readily apparent after the second decade. Night blindness and field loss can also develop later in life due to expanding areas of choroioretinal atrophy in females (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v22/n4/full/ejhg2013183a.html">Clinical Utility Gene Card</ext-link>) [<xref ref-type="bibr" rid="choroid.REF.moosajee.2014">Moosajee et al 2014</xref>]. Females who demonstrate clinical findings that mimic those of affected males likely have skewed X-chromosome inactivation.Symptomatic but mildly affected females are likely underreported in the literature.</p>
        </sec>
        <sec id="choroid.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations have not yet been demonstrated for this disorder.</p>
        </sec>
        <sec id="choroid.Nomenclature">
          <title>Nomenclature</title>
          <p>Choroideremia, the only diagnostic term used for this condition, has consistently been applied for more than 130 years.</p>
        </sec>
        <sec id="choroid.Prevalence">
          <title>Prevalence</title>
          <p>Prevalence is estimated at 1:50,000.</p>
        </sec>
      </sec>
      <sec id="choroid.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>CHM is typically an isolated finding; it may rarely be part of a contiguous gene syndrome involving Xq21.</p>
        <list list-type="bullet">
          <list-item>
            <p>Males with large interstitial deletions involving Xq21 and additional X-chromosome material may have CHM, severe cognitive deficits, and birth defects such as cleft lip and palate and agenesis of the corpus callosum [<xref ref-type="bibr" rid="choroid.REF.schwartz.1996.33">Schwartz &#x00026; Rosenberg 1996</xref>].</p>
          </list-item>
          <list-item>
            <p>Males who have a small deletion involving Xq21 may have CHM, mixed sensorineural and conductive hearing loss (caused by deletion of <italic toggle="yes">POU3F4</italic>), and varying degrees of cognitive deficits (caused by deletion of <italic toggle="yes">RSK4</italic>) [<xref ref-type="bibr" rid="choroid.REF.yntema.1999.332">Yntema et al 1999</xref>].</p>
          </list-item>
          <list-item>
            <p>A contiguous gene deletion of Xq21 has been reported in a female with premature ovarian failure (POF) and mixed conductive and sensorineural deafness. This deletion was due to a <italic toggle="yes">de novo</italic> X;4 chromosome translocation [<xref ref-type="bibr" rid="choroid.REF.lordasanchez.2000.185">Lorda-Sanchez et al 2000</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="choroid.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Laboratory analysis may not always support the clinical diagnosis of choroideremia (CHM). For instance, a study identified 13 individuals who had a clinical diagnosis of CHM without a lab test confirmation [<xref ref-type="bibr" rid="choroid.REF.lee.2003.364">Lee et al 2003</xref>]. On reassessment of available clinical data, alternate diagnoses were suggested for eight of the 13 patients. Specifically, CHM needs to be distinguished from the following retinal dystrophies:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter"><bold>Retinitis pigmentosa</bold></related-object>
<bold>(RP)</bold> is a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) of the retina lead to progressive visual loss. The symptoms of RP (i.e., "night blindness" and constriction of peripheral visual field) are similar to those of CHM. In the later stages of CHM, when the loss of choroid and retina are significant, the fundus appearance may be confused with end-stage RP; however, the degree of migration of pigment into the retina that typifies RP is not seen in individuals with CHM. Diagnosis of RP relies on electroretinography (ERG) and visual field testing. RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Pathogenic variants in <italic toggle="yes">RPGR</italic> and <italic toggle="yes">RP2</italic> are the most common causes of X-linked RP, accounting for 70%-90% and 10%-20%, respectively, of X-linked RP. The pattern of autofluorescence retinal imaging in carriers of X-linked RP is distinct from that of CHM carriers [<xref ref-type="bibr" rid="choroid.REF.preising.2009">Preising et al 2009</xref>].</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="usher1" document-type="chapter"><bold>Usher syndrome type 1</bold></related-object> is characterized by congenital, bilateral, profound hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa. Unless fitted with a cochlear implant, individuals do not typically develop speech. Retinitis pigmentosa develops in adolescence, resulting in progressively constricted visual fields and impaired visual acuity. The diagnosis is established on clinical grounds using electrophysiologic and subjective tests of hearing and retinal function. Usher syndrome type 1 may be confused with the contiguous gene deletion syndrome, CHM and deafness with perilymphatic gusher. The scalloped areas of significant chorioretinal degeneration with preservation of the choroidal vessels, typical of CHM, are not seen in Usher syndrome type 1. Usher syndrome type I is inherited in an autosomal recessive manner. Mutation of genes at a minimum of nine different loci causes Usher syndrome type I. Genes at six of these loci &#x02013; <italic toggle="yes">MYO7A</italic> (USH1B), <italic toggle="yes">USH1C</italic>, <italic toggle="yes">CDH23</italic> (USH1D), <italic toggle="yes">PCDH15</italic> (USH1F), <italic toggle="yes">USH1G</italic>, and <italic toggle="yes">CIB2</italic> (USH1J) &#x02013; have been identified.</p>
          </list-item>
          <list-item>
            <p><bold>Gyrate atrophy of choroid and retina</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/258870">258870</ext-link>). The progressive nature of scalloped areas of chorioretinal atrophy seen in gyrate atrophy of the choroid and retina may be confused with CHM. Gyrate atrophy of the choroid and retina is an autosomal recessive condition caused by pathogenic variants in the gene encoding ornithine aminotransferase. Individuals with gyrate atrophy of the choroid and retina have elevated plasma concentration of ornithine, which is not seen in individuals with CHM.</p>
          </list-item>
        </list>
      </sec>
      <sec id="choroid.Management">
        <title>Management</title>
        <sec id="choroid.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with choroideremia (CHM), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Ophthalmologic examination including visual acuity and Goldmann visual field testing for a baseline</p>
            </list-item>
            <list-item>
              <p>Electroretinogram</p>
            </list-item>
            <list-item>
              <p>Funduscopic examination</p>
            </list-item>
            <list-item>
              <p>Optical coherence tomography (OCT)</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="choroid.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Retinal detachment which may occur more commonly in patients with high myopia (as seen in CHM) is treated by conventional surgical techniques by an ophthalmologist.</p>
          <p>Cataract surgery may be required for individuals with a posterior subcapsular cataract.</p>
          <p>UV-blocking sunglasses may have a protective role when an affected individual is outdoors.</p>
          <p>Low vision services are designed to benefit those whose ability to function is compromised by vision impairment. Low vision specialists, often optometrists, help optimize the use of remaining vision. Services provided vary based on age and needs.</p>
          <p>Counseling from organizations or professionals who work with the blind and visually impaired may be needed to help the affected individual cope with issues such as depression, loss of independence, fitness for driving, and anxiety over job loss.</p>
          <p>Nutrition and ocular health have become increasingly topical:</p>
          <list list-type="bullet">
            <list-item>
              <p>For those individuals who do not have access to fresh fruit and leafy green vegetables, a supplement with antioxidant vitamins may be important.</p>
            </list-item>
            <list-item>
              <p>No information is available on the effectiveness of vitamin A supplementation in the treatment of CHM.</p>
            </list-item>
            <list-item>
              <p>A source of omega-3 very-long-chain fatty acids, including docosahexaenoic acid, may be beneficial, as clinical studies suggest that a regular intake of fish is important.</p>
            </list-item>
          </list>
        </sec>
        <sec id="choroid.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>Rare cases of choroidal neovascularization may be treated with intravitreal bevacizumab [<xref ref-type="bibr" rid="choroid.REF.palejwala.2014.1675">Palejwala et al 2014</xref>]</p>
        </sec>
        <sec id="choroid.Surveillance">
          <title>Surveillance</title>
          <p>Regular ophthalmologic examination to monitor progression of CHM is recommended as affected individuals need advice regarding their levels of visual function. Goldmann visual field examinations provide practical information for both the clinician and the affected individual.</p>
          <p>Spectral domain-OCT (SD-OCT) is useful during therapeutic trials to measure macular thickness and the presence of cystoid macular edema [<xref ref-type="bibr" rid="choroid.REF.genead.2011.84">Genead &#x00026; Fishman 2011</xref>].</p>
        </sec>
        <sec id="choroid.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>UV exposure from sunlight reflected from water and snow should be avoided.</p>
        </sec>
        <sec id="choroid.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="choroid.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="choroid.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Gene therapy for individuals with CHM has been considered an achievable goal. Introduction of adenovirus containing the <italic toggle="yes">CHM</italic> coding region can restore in vitro protein levels and REP-1 activity in CHM-deficient lymphocytes and fibroblasts [<xref ref-type="bibr" rid="choroid.REF.anand.2003.919">Anand et al 2003</xref>].</p>
          <p><xref ref-type="bibr" rid="choroid.REF.vasireddy.2013.e61396">Vasireddy et al [2013]</xref> reported encouraging preclinical results using induced pluripotent stem cells from patients with CHM as in vitro models as well as normal-sighted mice as in vivo models. Delivery of <italic toggle="yes">CHM</italic> cDNA via a recombinant adeno-associated viral vector (AAV2) did not induce cytotoxicity in either model, suggesting that a human clinical trial for this condition is possible. To date, a safety trial of AAV2-mediated gene therapy in human subjects with CHM has been completed [<xref ref-type="bibr" rid="choroid.REF.maclaren.2014.1129">MacLaren et al 2014</xref>]. Despite the requirement for submacular placement of the vector through microsurgical techniques, no serious adverse events were noted.</p>
          <p><xref ref-type="bibr" rid="choroid.REF.morgan.2014.6381">Morgan et al [2014]</xref> provided supporting evidence that the retinal pigment epithelium and photoreceptor layers should be the primary targets for experimental therapies based on their high resolution retinal imaging studies.</p>
          <p>Other preclinical studies suggest that AAV8 may also be a candidate vector for choroideremia human gene therapy trials [<xref ref-type="bibr" rid="choroid.REF.black.2014.122">Black et al 2014</xref>].</p>
          <p>Note: Gene therapy trials for CHM are currently planned or underway and are registered with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="choroid.Other">
          <title>Other</title>
          <p><xref ref-type="bibr" rid="choroid.REF.genead.2012.826">Genead et al [2012]</xref> studied the use of 2% topical dorzolamide ophthalmic solution to treat two CHM patients with cystoids macular edema. Clear improvements in retinal thickness were identified though changes to visual acuity, retinal sensitivity and other functional measures were not clinically significant.</p>
        </sec>
      </sec>
      <sec id="choroid.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="choroid.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Choroideremia (CHM) is inherited in an X-linked manner.</p>
        </sec>
        <sec id="choroid.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have CHM nor will he be a carrier of the <italic toggle="yes">CHM</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected male, the mother of an affected male is an obligate carrier.</p>
            </list-item>
            <list-item>
              <p>If pedigree analysis reveals that the proband is the only affected family member, it is appropriate to examine the retina of the mother through a dilated pupil to determine if she has evidence of carrier status.</p>
            </list-item>
            <list-item>
              <p>Possible genetic explanations for a male proband with no family history of CHM (i.e., a simplex case) are:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The proband has a <italic toggle="yes">de novo</italic> pathogenic variant. In this instance, the proband's mother does not have a germline pathogenic variant and does not have the retinal changes seen in carriers. The only other family members at risk are the offspring of the proband.</p>
                </list-item>
                <list-item>
                  <p>The proband's mother has a <italic toggle="yes">de novo</italic> pathogenic variant and may or may not have the retinal changes seen in carriers. One of two types of <italic toggle="yes">de novo</italic> pathogenic variants may be present in the mother:</p>
                  <list list-type="alpha-lower">
                    <list-item>
                      <label>a</label>
                      <p>A germline variant that was present at the time of her conception, is present in every cell of her body, and is detectable in her DNA; or</p>
                    </list-item>
                    <list-item>
                      <label>b</label>
                      <p>A pathogenic variant that is present only in her ovaries (termed "germline mosaicism") and is not detectable in the DNA from her leukocytes.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Germline mosaicism has not been reported in individuals with CHM but it has been observed in many X-linked disorders and should be considered in the genetic counseling of at-risk family members. In both instances a) and b), each offspring of the proband's mother is at risk of inheriting the pathogenic variant; none of the sibs of the proband's mother, however, is at risk of having inherited the altered gene.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of a proband depends on the genetic status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother has the pathogenic variant, the chance of transmitting the <italic toggle="yes">CHM</italic> pathogenic variant in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be affected; female sibs who inherit the pathogenic variant will be carriers and will usually not be affected.</p>
            </list-item>
            <list-item>
              <p>When the mother has a normal fundus examination, the risk to the sibs of a proband appears to be low. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a male proband.</bold> Affected males transmit the pathogenic variant to all of their female offspring and none of their male offspring.</p>
          <p><bold>Family members of a proband.</bold> If a parent of the proband also has a pathogenic variant, his or her female family members may be at risk of being carriers (asymptomatic or symptomatic) and his or her male family members may be at risk of being affected, depending on their genetic relationship to the proband.</p>
        </sec>
        <sec id="choroid.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing of at-risk female relatives is possible if the <italic toggle="yes">CHM</italic> pathogenic variant has been identified in the family.</p>
        </sec>
        <sec id="choroid.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>Specific risk issues.</bold> It is not possible to predict at what age an affected male will start to experience vision problems and how quickly the disease will progress. It is also not possible to know if a carrier female will manifest any vision loss. At one time, consensus held that carrier females experienced only mild vision disturbances later in life; however, manifesting carriers may have vision loss similar to that of affected males because of skewed X-chromosome inactivation.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="choroid.Prenatal_Testing_and_Preimplanta">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">CHM</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for choroideremia are possible.</p>
          <p>Requests for prenatal testing for conditions which (like CHM) do not affect intellect are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="choroid.Resources">
        <title>Resources</title>
      </sec>
      <sec id="choroid.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The gene comprises 15 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="choroid" object-id="choroid.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Nearly all known <italic toggle="yes">CHM</italic> pathogenic variants are nonsense variants, small deletions or insertions, or splice site alterations that predict or result in truncation of the protein product (REP-1).</p>
        <p>An exception is the report of a pathogenic L1 retrotransposon insertion in exon 6 that results in the direct splicing of exon 5 to exon 7 with maintenance of the reading frame. The missing amino acids are part of a conserved region that forms a hydrophobic groove that is proposed to bind geranyl-geranyl groups [<xref ref-type="bibr" rid="choroid.REF.van_den_hurk.2003.268">van den Hurk et al 2003</xref>].</p>
        <p>Few missense variants have been reported.</p>
        <table-wrap id="choroid.T.chm_pathogenic_variants_discus" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p><italic toggle="yes">CHM</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1609+2dupT</td>
                <td headers="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 1</td>
                <td headers="hd_h_choroid.T.chm_pathogenic_variants_discus_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000390.2">NM_000390.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000381.1">NP_000381.1</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="choroid.TF.2.1">
              <label>1. </label>
              <p>Splice site variant</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Rab escort protein-1 (REP-1) is a component of Rab geranylgeranyltransferase, an enzyme complex that mediates correct intracellular vesicular transport.</p>
        <p>The REP-1 protein functions in the prenylation (covalent addition of 20-carbon geranylgeranyl units) to Rab GTPases. Lymphocytes from individuals with CHM show marked inability to prenylate Rab proteins, in particular Rab27A. Rab proteins have a role in organelle formation and trafficking of vesicles in exocytic and endocytic pathways [<xref ref-type="bibr" rid="choroid.REF.seabra.2002.23">Seabra et al 2002</xref>]. In an individual with choroideremia, REP-2, encoded by <italic toggle="yes">CHML</italic> and functionally similar to REP-1, may compensate for the loss of REP-1 function in all non-retinal cells [<xref ref-type="bibr" rid="choroid.REF.cremers.1994.2111">Cremers et al 1994</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Most often the pathogenic variant predicts or results in a truncated product that is degraded based on absence of immunohistochemical staining of REP-1 protein in cells from peripheral tissues of individuals with CHM [<xref ref-type="bibr" rid="choroid.REF.macdonald.1998.1637">MacDonald et al 1998</xref>]. In silico analyses on the effect of a novel missense and other pathogenic variants on 3D structure of REP-1 have been reported [<xref ref-type="bibr" rid="choroid.REF.sergeev.2009.44">Sergeev et al 2009</xref>].</p>
      </sec>
      <sec id="choroid.References">
        <title>References</title>
        <sec id="choroid.Published_GuidelinesConsensus_St">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="choroid.Published_GuidelinesConsensus_St.reflist0">
            <ref id="choroid.REF1">
              <mixed-citation publication-type="web">American Academy of Ophthalmology Task Force on Genetic Testing. Recommendations for genetic testing of inherited eye diseases &#x02013; 2014. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.aao.org/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d">online</ext-link>. 2014. Accessed 3-2-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="choroid.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="choroid.Literature_Cited.reflist0">
            <ref id="choroid.REF.anand.2003.919">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anand</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barral</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunsmann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maguire</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus.</article-title>
                <source>Vision Res</source>
                <volume>43</volume>
                <fpage>919</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">12668061</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.black.2014.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasireddy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maguire</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaddameedi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolmachova</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models.</article-title>
                <source>J Gene Med.</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>122</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">24962736</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.cremers.1994.2111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armstrong</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>REP-2, a Rab escort protein encoded by the choroideremia-like gene.</article-title>
                <source>J Biol Chem.</source>
                <year>1994</year>
                <volume>269</volume>
                <fpage>2111</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">8294464</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.fujiki.1999.735">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fujiki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hotta</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayakawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mashima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshii</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayasaka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagami</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isashiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohba</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanai</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>REP-1 gene mutations in Japanese patients with choroideremia.</article-title>
                <source>Graefes Arch Clin Exp Ophthalmol</source>
                <volume>237</volume>
                <fpage>735</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">10447648</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.genead.2011.84">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Genead</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination.</article-title>
                <source>Eye (Lond)</source>
                <year>2011</year>
                <volume>25</volume>
                <fpage>84</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">20966974</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.genead.2012.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Genead</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAnany</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.</article-title>
                <source>Retina.</source>
                <year>2012</year>
                <volume>32</volume>
                <fpage>826</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">21886018</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.lee.2003.364">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McTaggart</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sieving</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heckenlively</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levin</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anhalt</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical diagnoses that overlap with choroideremia.</article-title>
                <source>Can J Ophthalmol</source>
                <volume>38</volume>
                <fpage>364</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12956277</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.lordasanchez.2000.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lorda-Sanchez</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibanez</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trujillo</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anabitarte</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Querejeta</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Alba</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimenez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Infantes</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Sandoval</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayuso</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Choroideremia, sensorineural deafness, and primary ovarian failure in a woman with a balanced X-4 translocation.</article-title>
                <source>Ophthalmic Genet</source>
                <volume>21</volume>
                <fpage>185</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11035551</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.macdonald.1998.1637">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mah</surname>
                    <given-names>DY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A practical diagnostic test for choroideremia.</article-title>
                <source>Ophthalmology</source>
                <volume>105</volume>
                <fpage>1637</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">9754170</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.maclaren.2014.1129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacLaren</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groppe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnard</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottriall</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolmachova</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seymour</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>During</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lotery</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Downes</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.</article-title>
                <source>Lancet.</source>
                <year>2014</year>
                <volume>383</volume>
                <fpage>1129</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">24439297</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.mctaggart.2002.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McTaggart</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mah</surname>
                    <given-names>DY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesslinger</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutational analysis of patients with the diagnosis of choroideremia.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>189</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">12203991</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.moosajee.2014">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moosajee</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GCM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for : Choroideremia.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2014</year>
                <volume>22</volume>
                <comment/>
                <pub-id pub-id-type="doi">10.1038/ejhg.2013.183</pub-id>
                <pub-id pub-id-type="pmid">23963298</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.morgan.2014.6381">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klinman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maguire</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maguire</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>High-resolution adaptive optics retinal imaging of cellular structure in choroideremia.</article-title>
                <source>Invest Ophthalmol Vis Sci.</source>
                <year>2014</year>
                <volume>55</volume>
                <fpage>6381</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">25190651</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.palejwala.2014.1675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palejwala</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauer</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab.</article-title>
                <source>Clin Ophthalmol.</source>
                <year>2014</year>
                <volume>8</volume>
                <fpage>1675</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">25214760</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.preising.2009">
              <mixed-citation publication-type="other">Preising MN, Wegscheider E, Friedburg C, Poloschek CM, Wabbels BK, Lorenz B. Fundus autofluorescence in carriers of choroideremia and correlation with electrophysiologic and psychophysical data. Ophthalmology. 2009;116:1201-9.e1-2.</mixed-citation>
            </ref>
            <ref id="choroid.REF.roberts.2002.658">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heckenlively</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grover</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia.</article-title>
                <source>Br J Ophthalmol</source>
                <volume>86</volume>
                <fpage>658</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">12034689</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.sankila.1992.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sankila</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolvanen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Hurk</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Chapelle</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Aberrant splicing of the CHM gene is a significant cause of choroideremia.</article-title>
                <source>Nat Genet.</source>
                <year>1992</year>
                <volume>1</volume>
                <fpage>109</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">1302003</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.schwartz.1996.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Prenatal diagnosis of choroideremia.</article-title>
                <source>Acta Ophthalmol Scand Suppl</source>
                <volume>219</volume>
                <fpage>33</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8741114</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.seabra.2002.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mules</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hume</surname>
                    <given-names>AN</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Rab GTPases, intracellular traffic and disease.</article-title>
                <source>Trends Mol Med</source>
                <volume>8</volume>
                <fpage>23</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">11796263</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.sergeev.2009.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sergeev</surname>
                    <given-names>YV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smaoui</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sui</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stiles</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordiyenko</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strunnikova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macdonald</surname>
                    <given-names>IM</given-names>
                  </name>
                </person-group>
                <article-title>The functional effect of pathogenic mutations in Rab escort protein 1.</article-title>
                <source>Mutat Res.</source>
                <year>2009</year>
                <volume>665</volume>
                <fpage>44</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">19427510</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.sieving.1986.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sieving</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niffenegger</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berson</surname>
                    <given-names>EL</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Electroretinographic findings in selected pedigrees with choroideremia.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>101</volume>
                <fpage>361</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3953730</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.van_den_hurk.1997.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van den Hurk</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Pol</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bogerd</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinckers</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleeker-Wagemakers</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pawlowitzki</surname>
                    <given-names>IH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruther</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropers</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene.</article-title>
                <source>Hum Mutat</source>
                <volume>9</volume>
                <fpage>110</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9067750</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.van_den_hurk.2003.268">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van den Hurk</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Pol</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wissinger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Driel</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoefsloot</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Wijs</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Born</surname>
                    <given-names>LI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heckenlively</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zrenner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropers</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Novel types of mutation in the choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon.</article-title>
                <source>Hum Genet</source>
                <volume>113</volume>
                <fpage>268</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">12827496</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.vasireddy.2013.e61396">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vasireddy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaddameedi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basner-Tschakarjan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohnke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexandrov</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maguire</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mac</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gadue</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennicelli</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>French</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models.</article-title>
                <source>PLoS One.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>e61396</fpage>
                <pub-id pub-id-type="pmid">23667438</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.yau.2007.147">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sereda</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McTaggart</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauve</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Choroideremia carriers maintain a normal electro-oculogram (EOG).</article-title>
                <source>Doc Ophthalmol</source>
                <volume>114</volume>
                <fpage>147</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17333094</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.yntema.1999.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yntema</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Helm</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Duijnhoven</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poppelaars</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chelly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moraine</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heilbronner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pander</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropers</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation.</article-title>
                <source>Genomics</source>
                <volume>62</volume>
                <fpage>332</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">10644430</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="choroid.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="choroid.Suggested_Reading.reflist0">
            <ref id="choroid.REF.cremers">
              <mixed-citation publication-type="book">Cremers FPM, Ropers HH. Choroideremia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 236. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="choroid.REF.macdonald.2009.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Choroideremia: new findings from ocular pathology and review of recent literature.</article-title>
                <source>Surv Ophthalmol</source>
                <volume>54</volume>
                <fpage>401</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19422966</pub-id>
              </element-citation>
            </ref>
            <ref id="choroid.REF.sandberg.2006.80">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sandberg</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudio</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Reading speed of patients with advanced retinitis pigmentosa or choroideremia.</article-title>
                <source>Retina</source>
                <volume>26</volume>
                <fpage>80</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16395143</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="choroid.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="choroid.Author_History">
          <title>Author History</title>
          <p>Stephanie Chan, MSc, CGC, CCGC (2015-present)Stacey Hume, PhD (2015-present)Ian M MacDonald, MD, CM (2003-present) Kerry McTaggart, MSc; University of Alberta (2003-2007) Meira R Meltzer, MA, MS, CGC; National Eye Institute (2007-2010) Miguel C Seabra, MD, PhD (2003-present) Christina Sereda, MSc; University of Alberta (2003-2007) Nizar Smaoui, MD; GeneDx (2007-2015)</p>
        </sec>
        <sec id="choroid.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 February 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>3 June 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 May 2008 (cd) Revision: duplication/deletion analysis available clinically</p>
            </list-item>
            <list-item>
              <p>3 May 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>29 December 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 January 2004 (im) Revision: testing</p>
            </list-item>
            <list-item>
              <p>7 May 2003 (im) Revision: Molecular genetic testing; prenatal diagnosis</p>
            </list-item>
            <list-item>
              <p>21 February 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 December 2002 (im) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
